These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17161064)

  • 21. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
    Pearson EC; Woosley RL
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship between torsades de pointes and QT dispersion in idiopathic long QT syndrome].
    Zhao F
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1312-3. PubMed ID: 16234119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
    Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
    J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced torsades de pointes in patients aged 80 years or more.
    Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac channelopathies: it's in the genes.
    Ackerman MJ
    Nat Med; 2004 May; 10(5):463-4. PubMed ID: 15122246
    [No Abstract]   [Full Text] [Related]  

  • 26. Fragment-based prediction of the clinical occurrence of long QT syndrome and torsade de pointes.
    Clark M; Wiseman JS
    J Chem Inf Model; 2009 Nov; 49(11):2617-26. PubMed ID: 19894674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between genetic variants in myocardial sodium and potassium channel genes and QT interval duration in diabetics: the Diabetes Heart Study.
    Lehtinen AB; Daniel KR; Shah SA; Nelson MR; Ziegler JT; Freedman BI; Carr JJ; Herrington DM; Langefeld CD; Bowden DW
    Ann Noninvasive Electrocardiol; 2009 Jan; 14(1):72-9. PubMed ID: 19149796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ankyrin-B syndrome: a case of sinus node dysfunction, atrial fibrillation and prolonged QT in a young adult.
    Robaei D; Ford T; Ooi SY
    Heart Lung Circ; 2015 Feb; 24(2):e31-4. PubMed ID: 25456501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
    Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
    J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes.
    Kääb S; Crawford DC; Sinner MF; Behr ER; Kannankeril PJ; Wilde AA; Bezzina CR; Schulze-Bahr E; Guicheney P; Bishopric NH; Myerburg RJ; Schott JJ; Pfeufer A; Beckmann BM; Martens E; Zhang T; Stallmeyer B; Zumhagen S; Denjoy I; Bardai A; Van Gelder IC; Jamshidi Y; Dalageorgou C; Marshall V; Jeffery S; Shakir S; Camm AJ; Steinbeck G; Perz S; Lichtner P; Meitinger T; Peters A; Wichmann HE; Ingram C; Bradford Y; Carter S; Norris K; Ritchie MD; George AL; Roden DM
    Circ Cardiovasc Genet; 2012 Feb; 5(1):91-9. PubMed ID: 22100668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.
    Khan IA; Gowda RM
    Int J Cardiol; 2004 May; 95(1):1-6. PubMed ID: 15159030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-point mutation in the selectivity filter site of the KCNQ1 potassium channel results in a severe phenotype, LQT1, of long QT syndrome.
    Ikrar T; Hanawa H; Watanabe H; Okada S; Aizawa Y; Ramadan MM; Komura S; Yamashita F; Chinushi M; Aizawa Y
    J Cardiovasc Electrophysiol; 2008 May; 19(5):541-9. PubMed ID: 18266681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes.
    Priori SG; Napolitano C
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):89-92. PubMed ID: 12090900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility genes & modifiers for cardiac arrhythmias.
    Schulze-Bahr E
    Prog Biophys Mol Biol; 2008; 98(2-3):289-300. PubMed ID: 19351519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene mutations associated with atrioventricular block complicated by long QT syndrome.
    Nishizaki M; Hiraoka M
    Circ J; 2010 Nov; 74(12):2546-7. PubMed ID: 21088333
    [No Abstract]   [Full Text] [Related]  

  • 37. Iron Overload Leading to Torsades de Pointes in β-Thalassemia and Long QT Syndrome.
    Refaat MM; El Hage L; Steffensen AB; Hotait M; Schmitt N; Scheinman M; Badhwar N
    Card Electrophysiol Clin; 2016 Mar; 8(1):247-56. PubMed ID: 26920202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-induced long QT syndrome and exome sequencing: Chinese shadows link past and future.
    Crotti L; Schwartz PJ
    J Am Coll Cardiol; 2014 Apr; 63(14):1438-40. PubMed ID: 24561140
    [No Abstract]   [Full Text] [Related]  

  • 39. Promoting arrhythmia susceptibility.
    Bunch TJ; Ackerman MJ
    Circulation; 2006 Jan; 113(3):330-2. PubMed ID: 16432063
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of ranolazine in long-QT syndrome type 3.
    Kaufman ES
    J Cardiovasc Electrophysiol; 2008 Dec; 19(12):1294-5. PubMed ID: 18662183
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.